相关实验视频

Updated: Jan 10, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

无胺毒素A 预防伴随性 Bruxism 的慢性偏头痛:来自 GRASP 研究小组的现实世界数据

Andreas A Argyriou¹, Emmanouil V Dermitzakis², Maria Chondrogianni³

¹Headache Outpatient Clinic, Department of Neurology, Agios Andreas State General Hospital of Patras, 26335 Patras, Greece.

|November 26, 2025

概括

无胺毒素A (BoNTA) 治疗显著降低了慢性偏头痛的频率和与 Bruxism 相关的疼痛. Bruxism 严重程度的改善与偏头痛日数的减少直接相关,这表明双重治疗效益.

科学领域:

神经学神经学
疼痛管理疼痛管理
药理学药理学是指药理学的学科.

背景情况:

慢性偏头痛 (CM) 常常与 Bruxism 同时发生,影响患者的生活质量.
希腊研究联盟研究头痛和疼痛 (GRASP) 调查了潜在的治疗联系.
毒素A (BoNTA) 是这两种疾病的潜在治疗方法.

研究的目的:

评估两个连续的OnabotulinumtoxinA (BoNTA) 循环在改善慢性偏头痛 (CM) 频率和严重性的有效性.
探索BoNTA诱导的布鲁克西斯症缓解对偏头痛结果的影响.

主要方法:

58名患有并发性 Bruxism 的 CM 患者每季度接受两次 BoNTA 循环.
用PI-NRS尺度测量布鲁克西斯疼痛.
布鲁克斯症诊断和表型变化通过Bruxscreen-Q问卷进行评估.

主要成果:

BoNTA显著降低了 Bruxism 疼痛 (PI-NRS 中位数从 7 到 3, p < 0.001).
马塞特缩显著下降 (p < 0.001),而布鲁克斯屏-Q分数有所改善.
观察到70.7%的患者对BoNTA的反应率,头痛日减少与疼痛改善相关 (r=0.710,p < 0.001).

结论:

在慢性偏头痛和并发性 Bruxism 中,OnabotulinumtoxinA (BoNTA) 提供了双重的好处.
博恩塔有效地减少了偏头痛的频率,并缓解了与布鲁克斯症相关的疼痛.
对偏头痛和 Bruxism 的积极影响似乎相互关联.

关键词:

波恩塔 (BoNTA) 是一个名为博恩塔的小镇.它是一种玻丁毒素A.布鲁克斯主义是什么意思慢性偏头痛慢性偏头痛慢性偏头痛这种疾病是共患的.

更多相关视频

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

相关概念视频

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...